Chinook Therapeutics, Inc. KDNY
Set alert
40.39 +40.39 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 2.63B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -11.37
- Beta
- 0.68
- Short ratio
- 1.24
- Inst. own
- 96.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2023
- 50-d avg
- 29.15
- 200-d avg
- 24.27
- 1y target
- 39.30
2Y chart
Events in this range
- May 12, 2022Earnings: —; estimate -0.68; surprise —%
- Aug 8, 2022Earnings: —; estimate -0.62; surprise —%
- Nov 10, 2022Earnings: —; estimate -0.62; surprise —%
- Feb 27, 2023Earnings: —; estimate -0.79; surprise —%
- May 9, 2023Earnings: —; estimate -0.8; surprise —%
- Jun 12, 2023Downgrade: Cantor Fitzgerald · Overweight → Neutral
- Jun 13, 2023Downgrade: HC Wainwright & Co. · Buy → Neutral
- Jun 13, 2023Downgrade: SVB Leerink · Outperform → Market Perform
- Jun 13, 2023Downgrade: Stifel · Buy → Hold
- Jun 14, 2023Downgrade: Evercore ISI Group · Outperform → In-Line
- Jun 21, 2023Rating: HC Wainwright & Co. · Neutral → Neutral
- Aug 7, 2023Earnings: —; estimate -0.81; surprise —%
Signals (62)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Jun 30, 2023 | 3 years ago |
| RSI: Overbought | Jun 12, 2023 | 3 years ago |
| SMA: Bullish | May 26, 2023 | 3 years ago |
| SMA: Bullish | May 26, 2023 | 3 years ago |
| SMA: Bearish | May 23, 2023 | 3 years ago |
| SMA: Bullish | May 22, 2023 | 3 years ago |
| SMA: Bearish | May 17, 2023 | 3 years ago |
| SMA: Bearish | May 17, 2023 | 3 years ago |
| SMA: Bullish | May 10, 2023 | 3 years ago |
| SMA: Bullish | May 10, 2023 | 3 years ago |
| MACD: Buy Signal | May 8, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 27, 2023 | 3 years ago |
| SMA: Bearish | Apr 20, 2023 | 3 years ago |
| SMA: Bullish | Apr 19, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 19, 2023 | 3 years ago |
| SMA: Bearish | Apr 10, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 10, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 24, 2023 | 3 years ago |
| SMA: Bullish | Mar 23, 2023 | 3 years ago |
| SMA: Bearish | Mar 22, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 21, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 3, 2023 | 3 years ago |
| SMA: Bearish | Feb 3, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 3, 2023 | 3 years ago |
| RSI: Overbought | Dec 22, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 1, 2022 | 3 years ago |
| SMA: Bullish | Nov 30, 2022 | 3 years ago |
| SMA: Bearish | Nov 25, 2022 | 3 years ago |
| SMA: Bullish | Nov 23, 2022 | 3 years ago |
| SMA: Bearish | Nov 21, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| SMA: Bearish | Oct 19, 2022 | 4 years ago |
| SMA: Bullish | Oct 18, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 13, 2022 | 4 years ago |
| SMA: Bearish | Sep 21, 2022 | 4 years ago |
| SMA: Bullish | Sep 20, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 14, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 9, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 26, 2022 | 4 years ago |
| RSI: Overbought | Aug 16, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 4, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 30, 2022 | 4 years ago |
| SMA: Bullish | May 27, 2022 | 4 years ago |
| SMA: Bearish | May 25, 2022 | 4 years ago |
| SMA: Bullish | May 24, 2022 | 4 years ago |
| SMA: Bearish | May 23, 2022 | 4 years ago |
| SMA: Bullish | May 20, 2022 | 4 years ago |
| MACD: Buy Signal | May 20, 2022 | 4 years ago |
| SMA: Bearish | May 5, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 7, 2022 | 4 years ago |
| RSI: Overbought | Apr 1, 2022 | 4 years ago |
| RSI: Overbought | Mar 29, 2022 | 4 years ago |
| RSI: Overbought | Mar 25, 2022 | 4 years ago |
| SMA: Bullish | Mar 16, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 9, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 4, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 4, 2022 | 4 years ago |
| RSI: Oversold | Jan 27, 2022 | 4 years ago |
| MACD: Sell Signal | Dec 29, 2021 | 4 years ago |
| MACD: Buy Signal | Dec 27, 2021 | 4 years ago |
Key statistics
- Market cap
- 2.63B
- Enterprise value
- 2.30B
- Trailing P/E
- 0.00
- Forward P/E
- -11.37
- PEG ratio
- -1.36
- Price / sales
- 500.03
- Price / book
- 6.35
- EPS (TTM)
- -3.23
- Beta
- 0.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 5.26M
- Revenue growth
- -32.20%
- Free cash flow
- -84.44M
- Total cash
- 350.38M
- Total debt
- 38.26M
- Return on equity
- -51.56%
- Shares outstanding
- 67.05M
- Short % of float
- 5.44%
- 50-day average
- 29.15
- 200-day average
- 24.27
Analyst view
Consensus: buy
Buy
Price target (mean) 39.30 -2.7% downside
Now 40.39
- Target (low)
- 30.00
- Target (mean)
- 39.30
- Target (high)
- 47.00
Next earnings
Aug 7, 2023
Expected Aug 7, 2023. Consensus EPS estimate -0.81.
Financials — quick view
KDNY Revenue — quarterly 1.01M
KDNY Net income — quarterly -66.94M
KDNY EPS — quarterly -0.94
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2023 | Jun 1, 2023 | -0.81 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.80 | — | — | — |
| Feb 27, 2023 | Dec 1, 2022 | -0.79 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -0.62 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.62 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.68 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 21, 2023 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Jun 14, 2023 | Evercore ISI Group | down | Outperform | In-Line |
| Jun 13, 2023 | Stifel | down | Buy | Hold |
| Jun 13, 2023 | SVB Leerink | down | Outperform | Market Perform |
| Jun 13, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 12, 2023 | Cantor Fitzgerald | down | Overweight | Neutral |
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- chinooktx.com
News
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- Novartis Completes Acquisition of Chinook Therapeutics
- INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc (KDNY)
- INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
Your note
Sign in to keep a note on KDNY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Conversion of Exercise of derivative security | May 25, 2023 | 3,300 |
| BJERKHOLT ERIC H | Chief Financial Officer | Sale | Feb 9, 2023 | 38,867 |
| DAVIS JEREL C | Director | Conversion of Exercise of derivative security | May 25, 2023 | 733,770 |
| DOBMEIER ERIC L | Chief Executive Officer | Sale | Apr 23, 2023 | 301,138 |
| GREENMAN WILLIAM MARINER | Director | Sale | May 29, 2023 | 23,643 |
| GRIFFIN MICHELLE RENEE | Director | Conversion of Exercise of derivative security | May 25, 2023 | 3,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 7.72% | 5,161,888 | 202.45M | Mar 30, 2023 |
| Frazier Life Sciences Management, L.P. | 6.50% | 4,345,559 | 170.43M | Mar 30, 2023 |
| Blackrock Inc. | 5.89% | 3,942,539 | 154.63M | Mar 30, 2023 |
| Deep Track Capital, LP | 4.49% | 3,000,000 | 117.66M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 4.26% | 2,847,835 | 111.69M | Mar 30, 2023 |
| State Street Corporation | 4.02% | 2,688,048 | 105.43M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.60% | 1,709,505 | 67.05M | Dec 30, 2022 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.24% | 1,476,666 | 57.91M | Feb 27, 2023 |
| iShares Russell 2000 ETF | 1.69% | 1,112,841 | 43.65M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 0.91% | 602,215 | 23.62M | Dec 30, 2022 |
| iShares Russell 2000 Value ETF | 0.77% | 509,205 | 19.97M | Feb 27, 2023 |
| Federated Hermes Kaufmann Fund | 0.68% | 450,000 | 17.65M | Jan 30, 2023 |